BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/11/2025 7:47:40 AM | Browse: 15 | Download: 152
 |
Received |
|
2025-05-20 07:13 |
|
Peer-Review Started |
|
2025-05-20 07:13 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-05-26 23:51 |
|
Revised |
|
2025-05-30 01:07 |
|
Second Decision |
|
2025-06-23 02:41 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-06-23 04:52 |
|
Articles in Press |
|
2025-06-23 04:52 |
|
Publication Fee Transferred |
|
2025-06-03 10:49 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-07-04 06:11 |
|
Publish the Manuscript Online |
|
2025-07-11 07:47 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zhi-Hao Zeng, Jin-Qing Liu, Min Zhang, Cai-Liang Qiu and Zhen-Yu Xu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| The Scientific Research Program of FuRong Laboratory |
No. 2023SK2108 |
| Clinical Medical Research Center for Viral Hepatitis of Hunan Province |
No. 2023SK4009 |
| Hunan Provincial Natural Science Foundation |
No. 2023JJ60440 |
| Hunan Provincial Health Commission Research Program |
No. 202303088786 |
|
| Corresponding Author |
Zhen-Yu Xu, PhD, Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, No. 139 People’s Middle Road, Changsha 410011, Hunan Province, China. xuzhenyu@csu.edu.cn |
| Key Words |
Cholesterol; Lipoprotein; Lipid profile; Hepatitis B virus; Tenofovir amibufenamide |
| Core Tip |
This 144-week dual-phase study investigated the long-term lipid and safety profile of tenofovir amibufenamide (TMF) in chronic hepatitis B patients. Through a randomized, double-blind comparison with tenofovir disoproxil fumarate (TDF) followed by a TDF-to-TMF switch, the trial revealed comparable antiviral efficacy, improved renal and bone safety, and a moderate elevation in lipid levels with TMF that stabilized after switch therapy. These findings support TMF as a viable first-line and sequential therapy option in real-world chronic hepatitis B management. |
| Publish Date |
2025-07-11 07:47 |
| Citation |
<p>Zeng ZH, Liu JQ, Zhang M, Qiu CL, Xu ZY. Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch. <i>World J Gastroenterol</i> 2025; 31(26): 109285</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i26/109285.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i26.109285 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
